Chemomab’s CM-101 Shows Promise in PSC Trial
Company Announcements

Chemomab’s CM-101 Shows Promise in PSC Trial

Chemomab Therapeutics (CMMB) has released an update.

Don't Miss out on Research Tools:

Chemomab Therapeutics has reported encouraging outcomes from a Phase 2 trial of CM-101, showcasing significant improvements in primary sclerosing cholangitis (PSC) symptoms, with positive effects on liver stiffness, bilirubin levels, and pruritis. The trial results, demonstrating CM-101’s safety and potential as a disease-modifying treatment, set the stage for a Phase 3 trial following discussions with the FDA. These developments indicate a promising horizon for PSC treatment, a condition currently lacking approved therapies.

For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyChemomab highlights clincial activity of CM-101 at The Liver Meeting 2024
TipRanks Auto-Generated NewsdeskChemomab Therapeutics Aligns Leadership Incentives with Shareholders
TipRanks Auto-Generated NewsdeskChemomab’s Positive Trial Results Boost Investor Confidence
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App